Brief: Addex Therapeutics Provides Update On Dipraglurant Blepharospasm Phase 2 Feasibility Clinical Study
27/05/2022 06:07
May 27 (Reuters) - ADDEX THERAPEUTICS LTD ADXN.S :
* PROVIDES UPDATE ON DIPRAGLURANT BLEPHAROSPASM PHASE 2
FEASIBILITY CLINICAL STUDY
* ANNOUNCED TODAY THAT OUTCOME OF A SMALL PHASE 2A
FEASIBILITY
STUDY OF DIPRAGLURANT IN PATIENTS WITH BLEPHAROSPASM WAS
INCONCLUSIVE AND DID NOT MEET ALL OF ITS OBJECTIVES
* A TOTAL OF 15 PATIENTS WERE ENROLLED INTO THIS
DOUBLE-BLIND,
PLACEBO CONTROLLED PHASE 2A FEASIBILITY STUDY
* A PHASE 2 STUDY OF ADX71149 IN EPILEPSY BEING CONDUCTED BY
OUR
PARTNER JANSSEN IS EXPECTED TO REPORT DATA IN Q4 2022
Source text for Eikon: ID:nGNE4c1yCh
Further company coverage: ADXN.S
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))